Evidence map›Paper›PMID 37536638›Full record

ArticlePharmacological research2023

Arrest of mouse preterm labor until term delivery by combination therapy with atosiban and mundulone, a natural product with tocolytic efficacy.

Shajila Siricilla, Christopher J Hansen, Jackson H Rogers, Debasmita De, Carolyn L Simpson, Alex G Waterson, Gary A Sulikowski, Stacey L Crockett, Naoko Boatwright, Jeff Reese and 3 more

Open access · goldAbstract read
In one paragraph

Article in Pharmacological research, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.9field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 4 citations in OpenAlex.

  1. Review
  2. Article
  3. Preventing Preterm Birth: The Search for Tocolytic Synergism.Reproductive sciences (Thousand Oaks, Calif.) · 2025
    Review
  4. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

13 authors at 2 institutions in 1 country.

Shajila SiricillaDivision of Neonatology, Department of Pediatrics, Vanderbilt University Medical Center, Nashville, TN, USA.
Christopher J HansenDivision of Neonatology, Department of Pediatrics, Vanderbilt University Medical Center, Nashville, TN, USA; Department of Pharmacology, Vanderbilt University, Nashville, TN, USA.
Jackson H RogersDivision of Neonatology, Department of Pediatrics, Vanderbilt University Medical Center, Nashville, TN, USA.
Debasmita DeDivision of Neonatology, Department of Pediatrics, Vanderbilt University Medical Center, Nashville, TN, USA.
Carolyn L SimpsonDivision of Neonatology, Department of Pediatrics, Vanderbilt University Medical Center, Nashville, TN, USA.
Alex G WatersonDepartment of Pharmacology, Vanderbilt University, Nashville, TN, USA; Department of Chemistry, Vanderbilt University, Nashville, TN, USA; Vanderbilt Institute of Chemical Biology, Vanderbilt University, Nashville, TN, USA.
Gary A SulikowskiDepartment of Chemistry, Vanderbilt University, Nashville, TN, USA; Vanderbilt Institute of Chemical Biology, Vanderbilt University, Nashville, TN, USA.
Stacey L CrockettDivision of Neonatology, Department of Pediatrics, Vanderbilt University Medical Center, Nashville, TN, USA.
Naoko BoatwrightDivision of Neonatology, Department of Pediatrics, Vanderbilt University Medical Center, Nashville, TN, USA.
Jeff ReeseDivision of Neonatology, Department of Pediatrics, Vanderbilt University Medical Center, Nashville, TN, USA; Department of Biomedical Engineering, Vanderbilt University, Nashville, TN, USA; Department of Cell and Developmental Biology, Vanderbilt University, Nashville, TN, USA.
Bibhash C PariaDivision of Neonatology, Department of Pediatrics, Vanderbilt University Medical Center, Nashville, TN, USA.
J NewtonDivision of Maternal Fetal Medicine, Department of Obstetrics and Gynecology, Vanderbilt University Medical Center, Nashville, TN, USA.
Jennifer L HeringtonDivision of Neonatology, Department of Pediatrics, Vanderbilt University Medical Center, Nashville, TN, USA; Department of Pharmacology, Vanderbilt University, Nashville, TN, USA. Electronic address: Jennifer.l.herington@vumc.org.
Vanderbilt University Medical Center · USVanderbilt University · US

Funding

Tumor Immunology and Microenvironment Research ProgramP30CA068485 · NCI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI Ben Ho Park · 1995 to 2026
$172.8M
TRAINING IN PHARMACOLOGICAL SCIENCEST32GM007628 · NIGMS · VANDERBILT UNIVERSITY · PI BARNETT, JOEY VICTOR, KAVALALI, EGE T · 1985 to 2022
$11.2M
Pharmacologic Contributors to Patent Ductus ArteriosusR01HL164327 · NHLBI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI REESE, JOHN JEFFREY · 2022 to 2025
$2.9M
Ductus Arteriosus Regulation by Anion ChannelsR01HL128386 · NHLBI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI LAMB, FRED S, REESE, JOHN JEFFREY · 2016 to 2019
$2.3M
Pre-clinical studies to repurpose FDA-approved drugs for tocolytic useR01HD098213 · NICHD · VANDERBILT UNIVERSITY MEDICAL CENTER · PI HERINGTON, JENNIFER L. · 2019 to 2023
$2.2M
Mechanism and prevention of lipopolysaccharide-induced early pregnancy complicationsR01HD094946 · NICHD · VANDERBILT UNIVERSITY MEDICAL CENTER · PI PARIA, BIBHASH CHANDRA · 2018 to 2022
$2.1M
Discovery of Novel Therapeutics for Inflammation Induced Preterm BirthR00HD108420 · NICHD · VANDERBILT UNIVERSITY MEDICAL CENTER · PI Shajila Siricilla · 2024 to 2026
$736k
Fluorescent and Luminescent Kinetic Imaging Plate ReaderS10OD021734 · OD · VANDERBILT UNIVERSITY · PI LINDSLEY, CRAIG · 2016 to 2016
$671k
Identifying Small Molecules that Regulate Uterine ContractionsR21HD088830 · NICHD · VANDERBILT UNIVERSITY MEDICAL CENTER · PI HERINGTON, JENNIFER L. · 2017 to 2018
$435k
Discovery of Novel Therapeutics for Inflammation Induced Preterm BirthK99HD108420 · NICHD · VANDERBILT UNIVERSITY MEDICAL CENTER · PI SIRICILLA, SHAJILA · 2022 to 2023
$215k
NCI NIH HHS P30 CA068485NHLBI NIH HHS R01 HL128386NHLBI NIH HHS R01 HL164327NICHD NIH HHS K99 HD108420NICHD NIH HHS R00 HD108420NICHD NIH HHS R01 HD094946NICHD NIH HHS R01 HD098213NICHD NIH HHS R21 HD088830NIGMS NIH HHS T32 GM007628NIH HHS S10 OD021734
6 · The paper itself

Abstract

There is a lack of FDA-approved tocolytics for the management of preterm labor (PL). In prior drug discovery efforts, we identified mundulone and mundulone acetate (MA) as inhibitors of in vitro intracellular Ca

Indexed as

Biological ProductsObstetric Labor, PrematurePremature BirthTocolytic AgentsAnimalsFemaleHumansInfant, NewbornMiceMifepristoneNifedipineVasotocinatosibanBiological ProductsMifepristoneNifedipineTocolytic AgentsVasotocinatosiban (Pubchem CID: 5311010)Drug combinationindomethacin (Pubchem CID: 3715)mifepristone (pubchem CID: 55245)Mundulonemundulone acetate (Pubchem CID: 6857790)mundulone (Pubchem CID: 4587968)Natural productsnifedipine (Pubchem CID: 4485)oxytocin acetate (Pubchem CID: 5771)Preterm birthPreterm laborTocolyticU46619 (Pubchem CID: 5311493)Uterus

Identifiers

PMID37536638
PMCPMC10712649
OpenAlexW4385462101

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.